Patient and Oncologist Preferences for ALK plus Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments

被引：0
|
作者：
Le, H. [1 ]
Coulter, J. [2 ]
Cappelleri, J. C. [2 ]
Lu, H. [3 ]
Quaife, M. [3 ]
Meginnis, K. [3 ]
Fernandez, G. [3 ]
Culver, K. [4 ]
Vaghela, S. [2 ]
Rifi, N. [2 ]
Stinchcombe, T. [5 ]
机构：
[1] Pfizer Inc, Fairfax, VA USA
[2] Pfizer Inc, New York, NY USA
[3] Evidera, Cambridge, England
[4] ALK Posit, Atlanta, GA USA
[5] Duke Hlth, Durham, NC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Preference; ALK; TKI;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.12B.05
引用
收藏
页码：S202 / S202
页数：1
相关论文
共 50 条
  • [11] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [12] COST ANALYSIS BETWEEN TYROSINE KINASE INHIBITOR VERSUS DOCETAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER
    Topibulpong, N.
    Tanasanvimon, S.
    Parinyanitikul, N.
    Sriuranpong, V
    VALUE IN HEALTH, 2010, 13 (07) : A512 - A513
  • [13] 10-year survivors treated with tyrosine kinase inhibitor for advanced non-small cell lung cancer
    Tanaka, Y.
    Umemura, S.
    Sugiyama, E.
    Sakai, T.
    Izumi, H.
    Zenke, Y.
    Matsumoto, S.
    Yoh, K.
    Goto, K.
    ANNALS OF ONCOLOGY, 2023, 34
  • [14] Tyrosine Kinase Inhibitor Gold Nanoconjugates for the Treatment of Non-Small Cell Lung Cancer
    Cryer, Alexander M.
    Chan, Cheuk
    Eftychidou, Anastasia
    Maksoudian, Christy
    Mahesh, Mohan
    Tetley, Teresa D.
    Spivey, Alan C.
    Thorley, Andrew J.
    ACS APPLIED MATERIALS & INTERFACES, 2019, 11 (18) : 16336 - 16346
  • [15] EGFR tyrosine kinase inhibitors in the treatment of advanced non-small cell lung cancer
    Kowalski, D. M.
    Krzakowski, M.
    Jaskiewicz, P.
    Janowicz-Zebrowska, A.
    Glogowski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [16] Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
    Thompson, Jonathan R.
    Menon, Smitha P.
    Dy, Grace K.
    ADMET AND DMPK, 2016, 4 (03): : 186 - 211
  • [17] Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
    Imase, R.
    Endo, S.
    Sasahara, Y.
    Shinmura, T.
    Ozawa, T.
    Majima, H.
    Hara, T.
    Shimada, H.
    Yamauchi, S.
    Sakakibara, Y.
    Kobayashi, A.
    Yamazaki, K.
    Jin, Y.
    Yamanaka, K.
    Matsubara, O.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1953 - S1953
  • [18] Clinical data and role of ceritinib a second-generation ALK tyrosine kinase inhibitor for the treatment of ALK positive non-small cell lung cancer
    Rothschild, Sacha I.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1173 - S1176
  • [19] MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
    Felip, E.
    Minotti, V.
    Soo, R.
    Wolf, J.
    Solomon, B.
    Tan, D. S. W.
    Ardizzoni, A.
    Lee, D. H.
    Sequist, L. V.
    Barlesi, F.
    Paz-Ares, L.
    Rodriguez-Abreu, D.
    Garcia Campelo, M. R.
    Sprauten, M.
    Djentuh, L. O'Sullivan
    Belli, R.
    Glaser, S.
    Zou, M.
    Giovannini, M.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2020, 31 : S829 - S830
  • [20] ALK inhibitors and advanced non-small cell lung cancer (Review)
    Rossi, Antonio
    Maione, Paolo
    Sacco, Paola Claudia
    Sgambato, Assunta
    Casaluce, Francesca
    Ferrara, Marianna Luciana
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (02) : 499 - 508
12345